Nuo De Su Yuan (Guangzhou) Biotechnology Co., Ltd – Trademark Portfolio
Entity Type: 99
Nuo De Su Yuan (Guangzhou) Biotechnology Co., Ltd holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 3 (Cosmetics & Cleaning) — 4 filings in this category. Currently, 2 trademarks are registered and 1 is pending. Notable registered marks include SIMCARE. The owner is based in Guangzhou.
Room 401 and 402, Building 22,
544 North Guangzhou Avenue, Tianhe Dist.
Guangzhou 510500 , CN
Showing of trademarks Trademarks
Trademark Classifications
Nuo De Su Yuan (Guangzhou) Biotechnology Co., Ltd's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does Nuo De Su Yuan (Guangzhou) Biotechnology Co., Ltd have?
Nuo De Su Yuan (Guangzhou) Biotechnology Co., Ltd has 4 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 pending, 1 abandoned.
What trademark classes does Nuo De Su Yuan (Guangzhou) Biotechnology Co., Ltd file in?
Nuo De Su Yuan (Guangzhou) Biotechnology Co., Ltd files trademarks across 1 Nice Classification class. The most active classes are Class 3 (Cosmetics & Cleaning). Class 3 covers bleaching preparations and other substances for laundry use; cleaning, polishing, scouring.
What are Nuo De Su Yuan (Guangzhou) Biotechnology Co., Ltd's most well-known trademarks?
Nuo De Su Yuan (Guangzhou) Biotechnology Co., Ltd's registered trademark portfolio includes well-known marks such as SIMCARE. These are among 2 currently registered trademarks in the portfolio.
What is Nuo De Su Yuan (Guangzhou) Biotechnology Co., Ltd's trademark registration success rate?
Nuo De Su Yuan (Guangzhou) Biotechnology Co., Ltd has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 1 application is pending review.